The Northside Hospital Blood and Marrow Transplant (BMT) Program is one of only 20 institutions/consortia from across the United States to be awarded a national grant by the National Heart, Lung and Blood Institute and the National Cancer Institute to recruit, examine and treat clinical study participants.
The grant is the result of Northside’s designation as a Core Clinical Center of the national Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a second consecutive term (July 2010-June 2017, July 2017-June 2024). Northside serves as the lead site of a consortium of core clinical centers that includes the University of Miami and Levine Cancer Institute.
“This recognition is a result of our ongoing excellence and commitment to improving outcomes for hematopoietic stem cell transplant patients,” said Asad Bashey, M.D., Ph.D., medical director of the BMT research program at Northside Hospital and the principle investigator in charge of the hospital’s application to the BMT CTN.
The BMT Program at Northside Hospital is one of the largest and most prominent BMT programs in the United States and performs the entire range of available hematopoietic transplants including those from matched unrelated, matched sibling and haploidentical donors, and cord blood transplants. In 2017, Northside had among the best survival outcomes in nation for a ninth consecutive year (2009-17), per data released by the National Marrow Donor Program and The Center for International Blood and Marrow Transplant Research.
BMT CTN was established to conduct large multi-institutional clinical trials that address important issues in hematopoietic stem cell transplantation and further the understanding of the best possible treatment approaches. Since 2001, the program has launched 44 trials, accruing nearly 9,500 participants.